



**PRECISION**  
THERAPEUTICS

## **Precision Therapeutics' Skyline Medical Division Widens Global Reach Through New Taiwanese Distribution Agreement with Winner Scientific**

January 25, 2019

### **Company Further Expands Global Outreach Through Exhibition at Arab Health Show in Dubai**

MINNEAPOLIS, Jan. 25, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) ("Precision" or "the Company") today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked [STREAMWAY® System](#) for automated, direct-to-drain medical fluid disposal, has continued the company's global expansion by completing a distribution agreement with medical supply distributor, Winner Scientific in Taiwan.

Established in 1999 in the North District of Taiwan, Winner Scientific focuses on the distribution of a variety of product lines for the surgical suite. The agreement between Winner Scientific and Skyline Medical marks the tenth such agreement with distribution partners throughout the world. Prior to the Winner Scientific deal, Skyline has secured distribution agreements with Century Scientific & Equipment Company in Kuwait; Device Technologies in Australia, Pacific Islands and New Zealand; MediBridge in Switzerland; MEDIURGE in Pakistan; Prenit World in India; Quadromed in Canada; Sesnebar in Saudi Arabia; Anifro in Bangladesh; and Aras in the United Arab Emirates. The company also maintains a direct sales representation in Belgium, France and Germany.

The Asia Pacific healthcare market is predicted to continue strong growth, due to expansion in the use of medical services as a result of improved access to universal healthcare across the region, given the incidence of chronic diseases rise in tandem with shifts in lifestyles and an aging population. This is coupled with a larger mix of urban and rural health centers, which results in issues around access and affordability. Skyline is poised to meet these increasing needs with its efficient STREAMWAY system, which will help meet the increased demand for hygiene and safety requirements in healthcare facilities for both staff and patients.

In addition, Skyline Medical continues to increase its global presence by exhibiting at the 44<sup>th</sup> Annual Arab Health Conference in Dubai from January 28-31, 2019. Arab Health has brought the latest innovations in healthcare from state-of-the-art imaging equipment to the most cost-effective disposables; developments in surgery to advances in prosthetics, Arab Health continues to be at the heart of healthcare in the Middle East with the largest collection of healthcare product manufacturers and service providers from more than 68 countries. Accompanying the exhibition is a number of business, leadership and Continuing Medical Education (CME) conferences and workshops.

"We remain focused on introducing STREAMWAY as the optimal fluid disposal system available worldwide and are very proud of the global footprint we have established to date, executing on our strategic directive to expand our worldwide market penetration through direct and distributor-driven channels," commented Dr. Carl Schwartz, chief executive officer of Precision Therapeutics. "In addition, we recognize the value of our STREAMWAY system for medical centers throughout the world, enabling them to have the most efficient, disposal system available, which will provide these regions with the potential for improved surgeon efficiency, shorter procedure times, reduced exposure to potentially infectious fluids, more rapid room turnover and no costly management of fluid canisters, all of which translates into better and most cost-effective healthcare."

To be added to the Precision Therapeutics' database, please email [Info@MoneyInfo-llc.com](mailto:Info@MoneyInfo-llc.com) with your email address. This is solely for the use of Precision Therapeutics and will not be sold or distributed to third parties.

#### **About the STREAMWAY System**

Skyline's revolutionary, FDA-cleared [STREAMWAY System](#) is the first true direct-to-drain fluid disposal system designed specifically for medical applications, such as radiology, endoscopy, urology and cystoscopy procedures. It connects directly to a facility's plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. It also provides unlimited capacity for increased efficiency in the operating room, which leads to greater profitability. Furthermore, the STREAMWAY eliminates canisters to reduce overhead costs and provides greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the U.S. For a demonstration please visit [www.skylinemedical.com](http://www.skylinemedical.com) or call 855-785-8855.

#### **Additional Information and Where to Find It**

*This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. This communication may be deemed to be solicitation material in respect of the proposed transaction between Precision Therapeutics Inc. ("Precision") and Helomics. In connection with the proposed transaction, Precision has filed a registration statement on Form S-4, containing an exchange offer prospectus, a proxy statement for the annual meeting of the stockholders of Precision, an information statement and other detailed information regarding the proposed merger and related matters (the "S-4") with the SEC.*

*Each of Precision and Helomics plans to mail the proxy statement/prospectus/information statement contained in the Form S-4 to its stockholders at a future date. The Form S-4 and proxy statement/prospectus/information statement contains important information about Precision, Helomics, the merger and related matters. Investors and stockholders should read carefully the proxy statement/prospectus/information statement and the other*

documents filed with the SEC in connection with the merger before they make any decision with respect to the merger. A copy of the merger agreement with respect to the merger has been filed by Precision as an exhibit to its Form 8-K dated October 26, 2018.

The identity of people who, under SEC rules, may be considered "participants in the solicitation" of Helomics stockholders in connection with the proposed merger, and a description of their interests, is disclosed in the S-4 filing made by Precision.

This communication is not a substitute for the registration statement, definitive proxy statement/prospectus/information statement or any other documents that Precision has filed or may file with the SEC or that Precision or Helomics may send to their respective security holders in connection with the proposed transaction.

**SECURITY HOLDERS OF HELOMICS ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT/PROSPECTUS/INFORMATION STATEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.**

The proxy statement/prospectus/information statement, the Form 8-K and all other documents filed with the SEC in connection with the merger will be made available to investors free of charge on Precision's website at [www.precisiontherapeutics.com](http://www.precisiontherapeutics.com). In addition, the proxy statement/prospectus, the Form 8-K and all other documents filed with the SEC in connection with the merger will be made available to investors free of charge by calling or writing to:

Bob Myers, Chief Financial Officer  
Precision Therapeutics Inc.  
2915 Commers Drive, Suite 900  
Eagan, MN 55121  
Tel: 651-389-4806

In addition to the Form S-4, the proxy statement/prospectus/information statement and the other documents filed with the SEC in connection with the merger, Precision is obligated to file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements and other information filed with the SEC at the SEC's public reference rooms at 450 Fifth Street, N.W., Washington, D.C. 20549 or at the other public reference rooms in New York, New York and Chicago, Illinois. Please call the SEC at 1-800-SEC-0330 for further information on the public reference rooms. Filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at [www.sec.gov](http://www.sec.gov).

#### **About Precision Therapeutics Inc.**

Precision Therapeutics (NASDAQ:AIPT) operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic, and biotech industries, and second, production of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal. For additional information, please visit [www.precisiontherapeutics.com](http://www.precisiontherapeutics.com).

Precision Therapeutics' medicine business is committed to improving the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to rich data diseases databases. This business has launched with Precision Therapeutics' investment in Helomics Corporation, a precision medicine company and integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace. In addition to its proprietary precision diagnostics for oncology, Helomics offers boutique CRO services that leverage their patient-derived tumor models, coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and a proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to our client's specific needs. Helomics is 25% owned by Precision Therapeutics. Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories. For more information, please visit [www.Helomics.com](http://www.Helomics.com).

Precision Therapeutics has also announced the formation of a subsidiary, TumorGenesis to pursue a new rapid approach to growing tumors in the laboratory, which essentially "fools" the cancer cells into thinking they are still growing inside the patient. Precision Therapeutics and Helomics have also announced a proposed joint venture with GLG Pharma focused on using their combined technologies to bring personalized medicines and testing to ovarian and breast cancer patients, especially those who present with ascites fluid (over one-third of patients). The growth strategy in this business includes securing new partnerships and considering acquisitions in the precision medicine space.

Sold through the Skyline Medical business of Precision Therapeutics, The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential liability. Skyline Medical's STREAMWAY System fully automates the collection, measurement, and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA and other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills each year in the U.S. For additional information, please visit [www.skylinemedical.com](http://www.skylinemedical.com).

#### **Forward-looking Statements**

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include (1) risks related to the proposed merger, including the fact that we may not complete the merger; we do not have complete information about Helomics; the combined company will not be able to continue operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the merger may be higher than expected; the merger may result in disruption of the Company's and Helomics' existing businesses, distraction of management and diversion of resources; delay in completion of the merger may significantly reduce the expected benefits; and the market price of the Company's common stock may decline as a result of the merger; (2) risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; and (3) other risks and uncertainties relating to the Company that include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms;

unexpected costs and operating deficits, and lower than expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, which are available for review at [www.sec.gov](http://www.sec.gov). This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Annual Report on Form 10-K, and subsequent reports and other filings at [www.sec.gov](http://www.sec.gov).

Contacts:

Investor Relations

Bret Shapiro, Managing Partner

CORE IR

(516) 222-2560

[brets@coreir.com](mailto:brets@coreir.com)

Media

Jules Abraham

CORE IR

917-885-7378

[julesa@coreir.com](mailto:julesa@coreir.com)

 [PrecisionTherapeutics\\_Lo  
\(002\).png](#)

Source: Precision Therapeutics Inc.